Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
09. August 2023 08:05 ET
|
Agile Therapeutics, Inc.
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to...
Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
26. Juli 2023 08:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report second quarter 2023 financial results before...
Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
26. Juni 2023 08:01 ET
|
Agile Therapeutics, Inc.
Twirla (levonorgestrel and ethinyl estradiol) transdermal system will be made available nationwide to members of MMCAP Infuse, effective July 1, 2023 MMCAP Infuse has over 26,000 member facilities...
Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning Services
23. Juni 2023 12:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 23, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today praised the Executive Order issued by President Biden that addresses...
Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
15. Juni 2023 16:05 ET
|
Agile Therapeutics, Inc.
FPA Women’s Health is the largest independent family planning service network in the United States, and the Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now the exclusive patch...
Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
13. Juni 2023 16:05 ET
|
Agile Therapeutics, Inc.
Agile Plans to Increase Twirla prescriptions filled through telemedicine platforms that utilize vitaCare, such as Twentyeight Health™ Partnership Expected to Augment Future Growth in the Retail...
Agile Therapeutics Announces Closing of $7.5 Million Public Offering
25. Mai 2023 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its...
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
22. Mai 2023 20:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its...
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
11. Mai 2023 16:05 ET
|
Agile Therapeutics, Inc.
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth...
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
08. Mai 2023 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the...